COMPASS Pathways' (NASDAQ: CMPSPhase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as newly published data demonstrate the therapy’s potential beyond the reduction of depression.

These outcomes point to greater improvement in anxiety, quality of life, positive and negative emotions, cognitive function and ability to take part in everyday tasks as reported by participants who received 25mg psilocybin single doses vs. those who received the 1mg single doses after three weeks. The 10 mg group also self-reported improvements as compared with the 1 mg group, although to a lower degree.


Quick Q&A With COMPASS 

The study's findings seem to make the case for psilocybin's multifaceted effect on a set of measures related to TRD, further supporting its development …

Full story available on